Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype

Journal of Clinical Hypertension

Volumn 12, Issue 8, 2010, Pages 653-660

  Gruson, Damien ^a   Rousseau, Michel F ^b   Ketelslegers, Jean Marie ^a   Hermans, Michel P ^a  

^a Endocrinology and Nutrition Unit   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

UROTENSIN II;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; UROTENSIN II BLOOD LEVEL;

AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PHENOTYPE; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; UROTENSINS;

EID: 77955235177     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2010.00336.x     Document Type: Article

References (40)

1. Bern HA, Lederis K. A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts. J Endocrinol 1969, 45(suppl):xi-xii.
2. Coulouarn Y, Lihrmann I, Jegou S. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci U S A 1998, 95:15803-15808.
3. Ames RS, Sarau HM, Chambers JK. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999, 401:282-286.
4. Maguire JJ, Davenport AP. Is urotensin-II the new endothelin? Br J Pharmacol 2002, 137:579-588.
5. Maguire JJ, Kuc RE, Wiley KE. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 2004, 25:1767-1774.
6. Ong KL, Lam KS, Cheung BM. Urotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther 2005, 19:65-75.
7. Chen YH, Yandle TG, Richards AM. Urotensin II immunoreactivity in the human circulation: evidence for widespread tissue release. Clin Chem 2009, 55:2040-2048.
8. Gruson D, Rousseau MF, Ahn SA. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 2006, 27:1527-1531.
9. Douglas SA, Tayara L, Ohlstein EH. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002, 359:1990-1997.
10. Ong KL, Wong LY, Cheung BM. The role of urotensin II in the metabolic syndrome. Peptides 2008, 29:859-867.
11. Wild S, Roglic G, Green A. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
12. Wild SH, Forouhi NG. What is the scale of the future diabetes epidemic, and how certain are we about it? Diabetologia 2007, 50:903-905.
13. Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
14. Meetoo D, McGovern P, Safadi R. An epidemiological overview of diabetes across the world. Br J Nurs 2007, 16:1002-1007.
15. Cooper ME, Bonnet F, Oldfield M. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens 2001, 14:475-486.
16. Cooper ME, Johnston CI. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000, 283:3177-3179.
17. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
18. Revkin JH, Shear CL, Pouleur HG. Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. Pharmacol Rev 2007, 59:40-53.
19. Zaninotto M, Mion MM, Novello E. New biochemical markers: from bench to bedside. Clin Chim Acta 2007, 381:14-20.
20. Takahashi K, Ghatei MA, Lam HC. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990, 33:306-310.
21. Van Beneden R, Gurne O, Selvais PL. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 2004, 10:490-495.
22. Totsune K, Takahashi K, Arihara Z. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 2004, 25:1809-1814.
23. Wenyi Z, Suzuki S, Hirai M. Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. Diabetologia 2003, 46:972-976.
24. Suzuki S, Wenyi Z, Hirai M. Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 2004, 25:1803-1808.
25. Silvestre RA, Egido EM, Hernandez R. Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur J Endocrinol 2004, 151:803-809.
26. Marco J, Egido EM, Hernandez R. Evidence for endogenous urotensin-II as an inhibitor of insulin secretion study in the perfused rat pancreas. Peptides 2008, 29:852-858.
27. Ong KL, Wong LY, Man YB. Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides 2006, 27:1659-1667.
28. Sheridan MA, Bern HA. Both somatostatin and the caudal neuropeptide, urotensin II, stimulate lipid mobilization from coho salmon liver incubated in vitro. Regul Pept 1986, 14:333-344.
29. McDonald J, Batuwangala M, Lambert DG. Role of urotensin II and its receptor in health and disease. J Anesth 2007, 21:378-389.
30. Sheridan MA, Plisetskaya EM, Bern HA. Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. Gen Comp Endocrinol 1987, 66:405-414.
31. Watanabe T, Suguro T, Kanome T. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 2005, 46:738-744.
32. Cirillo P, De Rosa S, Pacileo M. Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease. J Thromb Haemost 2008, 6:726-736.
33. Dai HY, Guo XG, Ge ZM. Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy. J Diabetes Complications 2008, 22:137-143.
34. Heringlake M, Kox T, Uzun O. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 2004, 121:129-136.
35. Lescot E, Bureau R, Rault S. Nonpeptide urotensin-II receptor agonists and antagonists: Review and structure-activity relationships. Peptides 2008, 29:680-690.
36. Trebicka J, Leifeld L, Hennenberg M. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 2008, 47:1264-1276.
37. Clozel M, Binkert C, Birker-Robaczewska M. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 2004, 311:204-212.
38. Clozel M, Hess P, Qiu C. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 2006, 316:1115-1121.
39. Totsune K, Takahashi K, Arihara Z. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 2003, 104:1-5.
40. Suguro T, Watanabe T, Ban Y. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 2007, 20:211-217.